Marco Boorsma
InvestorGeneral Partner at Forbion
Amsterdam, Netherlands
Writes $100K – $5M checks · typically $1.5M
Find your path to Marco
251 people in our graph share verified history with Marco — schools, employers, funds. One of them is your warm intro.
BirgitteunlockedMarco: together at Calluna Pharma (2025–2026)
×3Marco: together at DSM Pharmaceutical Products
Marco: together at Rectifypharma
×7Marco: together at University of Groningen
About
Marco Boorsma is a General Partner at Forbion, which he joined in 2007. Before Forbion, he was Business Development Director at DSM Pharmaceutical Products and worked on manufacturing processes for biosimilars at Cytos Biotechnology. He focuses on biotechnology, operations, and business development, with an emphasis on founding and managing new companies as part of Forbion's build strategy, and holds an MSc in Molecular Biology from the University of Groningen and a PhD in Biotechnology from ETH Zürich.
Invests in
Biotech
Experience
- ForbionGeneral Partnercurrent2017 — presentNaarden, The Netherlands
- ForbionPartner2014 — 2017Naarden, The Netherlands
- ForbionPrincipal2010 — 2014
- ForbionSenior Analyst2007 — 2010Naarden
- Calluna PharmaBoard Director at Calluna Pharmacurrent2024 — presentOslo, Norway
- Sitala BioBoard Director at Sitalacurrent2021 — presentCambridge, England, United Kingdom
- Rectify PharmaBoard Director at Rectify Pharmacurrent2021 — presentCambridge, Massachusetts, United States
- VectorYBoard Director at VectorY2021 — 2025Amsterdam, North Holland, Netherlands
- VectorYChief Executive Officer2020 — 2021Amsterdam, North Holland, Netherlands
- Oxitope PharmaChairman of the Board2020 — 2023Naarden, North Holland, Netherlands
- Engene Inc.Board Director at enGene2017 — 2023Montreal, Canada
- Inversago PharmaBoard Director at Inversago2020 — 2023Montreal, Quebec, Canada
- Escalier Biosciences B.V.Board Director at Escalier Biosciences2018 — 2023Nijmegen, The Netherlands
- Inflazome LtdBoard Director at Inflazome2018 — 2020Dubline, Ireland
- NorthSea TherapeuticBoard Director at NorthSea Therapeutics2017 — 2019Naarden, The Netherlands
- Milestone Pharmaceuticals, Inc.Board Director at Milestone Pharmaceuticals2017 — 2019Greater Montreal Metropolitan Area
- Exosome DiagnosticsObserver to the BoD2010 — 2018Cambridge, USA
- Prexton Therapeutics SABoard Director at Prexton Therapeutics2017 — 2018Netherlands
- RSPR Pharma ABBoard Director at RSPR Pharma2014 — 2018Greater Stockholm Metropolitan Area
- OxyraneObserver to the BoD2011 — 2017Manchester Area, United Kingdom
- Akarna TherapeuticsBoard Director at Akarna Therapeutics2016London, United Kingdom
- ReplimuneBoard Director2015Oxford, United Kingdom
- Dezima PharmBoard Director2013 — 2015Naarden, The Netherlands
- Cardoz ABObserver to the BoD2010 — 2014Greater Stockholm Metropolitan Area
- DSM Pharmaceutical ProductsDirector of Business Development and Licensing2005 — 2007
- DSM Pharmaceutical ProductsProject Manager2004Netherlands
- DSM Pharmaceutical ProductsSenior Scientist2001 — 2004
- Cytos BiotechologyPhD Student1998 — 2001
- ETH ZurichPhD Student1998 — 2001
Skills & more
Strategy3Venture Capital12Contract Manufacturing3Biotechnology29Molecular Biology11Biochemistry5Clinical Development9Cell Culture6Lifesciences3Biopharmaceuticals3Licensing2Business Development3
+12 more
R&DPharmaceutical IndustryDrug DevelopmentStart-upsPatentsIntellectual PropertyVaccinesValidationEntrepreneurshipImmunologyMergers & AcquisitionsMedical DevicesFrom Marco's professional profile.
Deals · 1
Milestone PharmaceuticalsBoard seat
via Forbion · filed Jul 2017 · $6.9M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
AkarnaCalluna PharmaenGeneInflazomeInversagoOrbis MedicinesPrexton TherapeuticsPurespring TherapeuticsRectify PharmaReplimuneSidera BioSitalaVectorY Therapeutics
Investor
Dezima PharmaNorthSea TherapeuticsOxitope PharmaSidera
Sources: the firm's website · SEC Form D filings.
Colleagues at Forbion
Alexander Hoffmann
General Partner at Forbion
Alice Vickers
Advisor at Forbion
Antoine Boulanger Piette
Principal at Forbion
Audrey Cacaly
Principal at Forbion
Carlo Incerti
Operating Partner at Forbion
Dirk Kersten
Managing Partner at Forbion
Dmitrij Hristodorov
General Partner at Forbion
Geert-Jan Mulder
Managing Partner at Forbion
Network1
Investors connected to Marco in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Marco Boorsma?
- Marco Boorsma is a General Partner at Forbion, which he joined in 2007. Before Forbion, he was Business Development Director at DSM Pharmaceutical Products and worked on manufacturing processes for biosimilars at Cytos Biotechnology. He focuses on biotechnology, operations, and business development, with an emphasis on founding and managing new companies as part of Forbion's build strategy, and holds an MSc in Molecular Biology from the University of Groningen and a PhD in Biotechnology from ETH Zürich.
- Where does Marco Boorsma work?
- Marco Boorsma is General Partner at Forbion.
- What does Marco Boorsma invest in?
- Marco Boorsma invests in Biotech.
- What check size does Marco Boorsma write?
- Marco Boorsma typically writes checks of $100K – $5M.
- What boards does Marco Boorsma sit on?
- Marco Boorsma holds tracked board seats at Akarna, Calluna Pharma, enGene, Inflazome, Inversago, Milestone Pharmaceuticals, Milestone Pharmaceuticals, Orbis Medicines, Prexton Therapeutics, Purespring Therapeutics.
- What companies has Marco Boorsma invested in?
- Investments tracked here include Dezima Pharma, NorthSea Therapeutics, Oxitope Pharma, Sidera.
- Where did Marco Boorsma go to school?
- Marco Boorsma studied at ETH Zürich (PhD, Biotechnology); University of Groningen (BS, Molecular Biology).
Same school
Also attended ETH Zürich323
Bastian HasslingerInvestor at Index VenturesCat WuInvestor at Index VenturesSteve VassalloInvestor at Foundation CapitalHelge DaebelPartner, Head of Water at Emerald Technology Ventures AgMaurin DaiInvestment Manager, Physical AI & Robotics at Emerald Technology Ventures AgChristoph FreiPartner, Head of Energy at Emerald Technology Ventures Ag
+ 317 more
Also attended University of Groningen183
Ragnar JongenInvestor at DN CapitalJelle Van de PutteFund Administrator at Capricorn Venture PartnersLaura LentzExecutive Assistant at Castle Island VenturesChristophe de MontillePartner at Beyond Capital VenturesPeter HaasjesHead of Investments at NoaberMarlene van LooProgramma manager at Noaber
+ 177 more
Shared employers
Also worked at Calluna Pharma3
Also worked at Engene Inc.5
Also worked at Exosome Diagnostics1
Also worked at DSM Pharmaceutical Products29
Fredric PetitPartner, Head of Materials & Packaging at Emerald Technology Ventures AgJung Lee, PhDVenture Partner at Adelphi Ventures Management, LlcMax Von PoelnitzPartner at Foothill VenturesRichard PietersExecutive & Growth Leader at Joyance PartnersMarieke SchoninghAdvisor at ChrysalixMichael TarinoTiltas Solutions at Empactful Capital
+ 23 more